DBD Strangle Strategy
DBD (Diebold Nixdorf, Incorporated), in the Technology sector, (Software - Application industry), listed on NYSE.
Diebold Nixdorf, Incorporated engages in the automating, digitizing, and transforming the way people bank and shop worldwide. It operates through two segments, Banking and Retail. The company offers cash recyclers and dispensers, intelligent deposit terminals, teller automation tools, and kiosk technologies, as well as physical security solutions; and front-end applications for consumer connection points and back-end platforms that manage channel transactions, operations and integration, and facilitate omnichannel transactions, endpoint monitoring, remote asset management, customer marketing, merchandise management, and analytics. It also provides banking product-related services comprising proactive monitoring and rapid resolution of incidents through remote service capabilities or an on-site visit; first- and second-line maintenance, preventive maintenance, and on-demand services; managed and outsourcing services, such as business processes, solution management, upgrades, and transaction processing; and cash management services. In addition, the company offers DN Vynamic software suite to simplify and enhance the consumer experience; mobile point of sale and self-checkout terminals; printers, scales, and mobile scanners; and banknote and coin processing systems. Additionally, it provides retail customer's product-related services, such as on-demand and professional services; maintenance and availability services; implementation services; managed mobility services; monitoring and advanced analytics; and store life-cycle management services.
DBD (Diebold Nixdorf, Incorporated) trades in the Technology sector, specifically Software - Application, with a market capitalization of approximately $2.49B, a trailing P/E of 23.43, a beta of 1.15 versus the broader market, a 52-week range of 46.47-89.05, average daily share volume of 450K, a public-listing history dating back to 2023, approximately 21K full-time employees. These structural characteristics shape how DBD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.15 places DBD roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on DBD?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current DBD snapshot
As of May 15, 2026, spot at $70.28, ATM IV 34.00%, IV rank 2.03%, expected move 9.75%. The strangle on DBD below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 245-day expiry.
Why this strangle structure on DBD specifically: DBD IV at 34.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a DBD strangle, with a market-implied 1-standard-deviation move of approximately 9.75% (roughly $6.85 on the underlying). The 245-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DBD expiries trade a higher absolute premium for lower per-day decay. Position sizing on DBD should anchor to the underlying notional of $70.28 per share and to the trader's directional view on DBD stock.
DBD strangle setup
The DBD strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DBD near $70.28, the first option leg uses a $75.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DBD chain at a 245-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DBD shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $75.00 | $7.80 |
| Buy 1 | Put | $65.00 | $5.55 |
DBD strangle risk and reward
- Net Premium / Debit
- -$1,335.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$1,335.00
- Breakeven(s)
- $51.65, $88.35
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
DBD strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on DBD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$5,164.00 |
| $15.55 | -77.9% | +$3,610.18 |
| $31.09 | -55.8% | +$2,056.36 |
| $46.62 | -33.7% | +$502.54 |
| $62.16 | -11.5% | -$1,051.28 |
| $77.70 | +10.6% | -$1,064.90 |
| $93.24 | +32.7% | +$488.91 |
| $108.78 | +54.8% | +$2,042.73 |
| $124.32 | +76.9% | +$3,596.55 |
| $139.85 | +99.0% | +$5,150.37 |
When traders use strangle on DBD
Strangles on DBD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the DBD chain.
DBD thesis for this strangle
The market-implied 1-standard-deviation range for DBD extends from approximately $63.43 on the downside to $77.13 on the upside. A DBD long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current DBD IV rank near 2.03% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on DBD at 34.00%. As a Technology name, DBD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DBD-specific events.
DBD strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DBD positions also carry Technology sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DBD alongside the broader basket even when DBD-specific fundamentals are unchanged. Always rebuild the position from current DBD chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on DBD?
- A strangle on DBD is the strangle strategy applied to DBD (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With DBD stock trading near $70.28, the strikes shown on this page are snapped to the nearest listed DBD chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are DBD strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the DBD strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 34.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,335.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a DBD strangle?
- The breakeven for the DBD strangle priced on this page is roughly $51.65 and $88.35 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current DBD market-implied 1-standard-deviation expected move is approximately 9.75%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on DBD?
- Strangles on DBD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the DBD chain.
- How does current DBD implied volatility affect this strangle?
- DBD ATM IV is at 34.00% with IV rank near 2.03%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.